Key Takeaways
- Galderma updated investors on the launch of Nemluvio in prurigo nodularis during the company’s nine-month sales report.
- Nemluvio marks Galderma’s first biologic drug launch and is competing against Sanofi/Regeneron’s power brand Dupixent.
- Since launching in August, the drug has gained a 25% market share of new prescriptions, and 1,100 physicians have prescribed it, CEO Flemming Ornskov said.
It’s still early days in the launch of Galderma’s IL-31 inhibitor Nemluvio (nemolizumab), but CEO Flemming Ornskov told the company’s nine-month sales and earnings call on 24 October that the launch of the firm’s first biologic
Nemluvio was approved by the US Food and Drug Administration in August for the treatment of prurigo nodularis (PN), a rare but debilitating skin condition that results in bumpy skin nodules and extreme itch
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?